Thomas Tan
Company: Immunitas Therapeutics
Job title: Chief Scientific Officer
Seminars:
Panel Discussion: A Brief History – Why Haven’t Advancements in Targeted- & Immunotherapies Had More Impact on GI Cancers? 8:30 am
With many promising candidates in targeted and immunotherapy simply not meeting expectations, where should we be looking? Understanding and translation of the pathologies of various GI cancers: MSS vs MSI CRC, HCC, PDAC & more Where is the field moving? Which tumors to focus certain therapeutics on? How will early detection, precision oncology & patient…Read more
day: Day One
Chair’s Opening Remarks 8:20 am
day: Day One